MUC5AC and mucinous neoplasm: Although no recurrence was observed during the median follow-up period of 17.5 months, longer surveillance is warranted for all patients to confirm the durability of complete responses, particularly in those with mucinous tumors, where residual mucin pools may persist and could harbor delayed recurrence (Figure 3).